CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010 Recall
CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010
FDA recall Class II
Ongoing
FDA lists this Class II recall for CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-0325-2027
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Sep 18, 2026
- FDA report date
- Nov 11, 2026
- Quantity in commerce
- 1
- Distribution
- See key details
- FDA cause
- Nonconforming Material/Component
What is being recalled?
CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010
Affected model & UDI checker
Search the exact identifiers published for Z-0325-2027.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| SGP010 | CryoPatch SynerGraft (SG) Pulmonary Human Cardiac Patch, Model: SGP010 | Check source notice | Not specified |
FDA code information
Serial/Donor Number: 12617554/177871, UDI-DI: 00877234000478, Shipped: 22May2024, Implanted: 05June2024
Why was this product recalled?
A cryopreserved pulmonary human cardiac patch, taken from a 64-year-old human donor, was outside the cardiac tissue donor age specification of newborn to 60 years. The patch was implanted, and due to limitations of long-term in vivo data, the possibility of premature graft dysfunction cannot be excluded.
What actions did Artivion, Inc take?
On 9/18/2026, the notification was delivered via mail to customer who was advised of the following: Available biomechanical and histological evidence does not indicate an increased risk that would warrant additional patient testing, enhanced clinical monitoring, or other clinical intervention beyond the patient's routine standard of care. Accordingly, prophylactic removal or surgical replacement of the already implanted tissue solely because of the donor-age nonconformance is not clinically warranted. Complete and return the response form via email to fieldassurance@artivion.com Firm requests that any observed deficiency, performance concern, or other issue potentially associated with the tissue be reported to them vial email: fieldassurance@artivion.com or phone: +1-770-419-3355
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-0325-2027
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 19, 2026
- openFDA device recall record · Source release Nov 14, 2026 · Retrieved Nov 19, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology